Polarean Imaging PLC to submit New Drug Application of its lung imaging system to the FDA in October

Polarean Imaging PLC (LON:PLLX) CEO Richard Hullihen tells Proactive the group has achieved one of its most important milestones to date, the positive readout from its Phase III clinical trials of its Xenon Polariser lung imaging system. Hullihen, who spoke to Proactive about the firm's 6 month interim results, says the US-based group expects to make the submission for approval of the product to the FDA as early as next month.